The company has started enrolling patients into a run-in period for the Phase III study, and plans to begin dosing later this ...
After JP Morgan, the company is focusing on getting ready to submit a biologics license application to the FDA for miv-cel in ...
The announcement comes on the heels of promising preliminary Phase II data, in which OCU410 reduced lesion growth in patients' eyes.
The grant will support a Phase I study of an anti-CD64 CAR T-cell therapy in patients with acute myeloid leukemia.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback